You are here

A Study Of CP-690,550 In Stable Kidney Transplant Patients

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Birmingham, Alabama, 35249-6860 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Kidney Transplant
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-70 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Medically stable kidney transplant patients 6 or more months after transplantation.

- Subjects must be on mycophenolate mofetil 1-2 gm daily

- In Cohort 3 (and 4, if conducted) in Stage 1 and the expanded cohort in Stage 2,
subjects must be on a calcineurin inhibitor-free regimen.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Any rejection episodes in the preceding 3 months.

- Treated with Thymoglobulin or OKT3 for acute rejection in the past 6 months.

NCT01710033
Pfizer
Completed
A Study Of CP-690,550 In Stable Kidney Transplant Patients

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now